MX9101956A - Prodrogas para beta-lactamasa y usos de los mismos - Google Patents

Prodrogas para beta-lactamasa y usos de los mismos

Info

Publication number
MX9101956A
MX9101956A MX9101956A MX9101956A MX9101956A MX 9101956 A MX9101956 A MX 9101956A MX 9101956 A MX9101956 A MX 9101956A MX 9101956 A MX9101956 A MX 9101956A MX 9101956 A MX9101956 A MX 9101956A
Authority
MX
Mexico
Prior art keywords
prodroges
lactamase
beta
Prior art date
Application number
MX9101956A
Other languages
English (en)
Inventor
John Kadow
Takushi Kaneko
Peter D Senter
Vivekananda M Vrudhula
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX9101956A publication Critical patent/MX9101956A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX9101956A 1990-11-06 1991-11-06 Prodrogas para beta-lactamasa y usos de los mismos MX9101956A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60966390A 1990-11-06 1990-11-06
US77037191A 1991-10-08 1991-10-08

Publications (1)

Publication Number Publication Date
MX9101956A true MX9101956A (es) 1992-07-08

Family

ID=27086090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9101956A MX9101956A (es) 1990-11-06 1991-11-06 Prodrogas para beta-lactamasa y usos de los mismos

Country Status (8)

Country Link
EP (2) EP0742015A1 (es)
JP (1) JPH04264089A (es)
AU (1) AU649275B2 (es)
CA (1) CA2055062A1 (es)
FI (1) FI915210A (es)
IE (1) IE913862A1 (es)
MX (1) MX9101956A (es)
ZA (1) ZA918738B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001137A1 (en) * 1992-07-06 1994-01-20 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9216759D0 (en) * 1992-08-07 1992-09-23 Finpael Spa Process for the production of 7-amino thiazolyl cephalosporins
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
GB9314562D0 (en) * 1993-07-14 1993-08-25 Erba Carlo Spa Use of cephem derivatives as anti-metastatic agents
ATE267798T1 (de) * 1994-01-28 2004-06-15 Univ Kentucky Res Found Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
CA2177644A1 (en) * 1995-05-31 1996-12-01 Peter D. Senter Polymeric prodrugs for beta-lactamase and uses thereof
JP2002510968A (ja) * 1997-05-07 2002-04-09 ブリストル−マイヤーズ スクイブ カンパニー 組換え抗体−酵素融合タンパク質
US6159706A (en) * 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
WO2000020608A1 (en) * 1998-10-02 2000-04-13 Genotherapeutics, Inc. Method of treating prostate cancer with an adenovirus expression vector encoding a prodrug enzyme
EP1254179A4 (en) 2000-01-24 2005-06-01 Univ Columbia IN VIVO SCRAP IMPLEMENTING DIMMERIZATION CHEMICAL INDUCERS
WO2001083492A1 (en) * 2000-05-02 2001-11-08 Newbiotics, Inc. Improved beta-lactam antibiotics
AU2001293555A1 (en) * 2000-09-21 2002-04-02 Novation Pharmaceuticals Inc. Benzoic acid derivatives and uses thereof
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP1735350B1 (en) * 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
CN108338982A (zh) * 2017-12-27 2018-07-31 天津国际生物医药联合研究院 头孢噻吩钠在抗白血病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509707A (en) * 1974-09-20 1978-05-04 Searle & Co Immunological compounds
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system

Also Published As

Publication number Publication date
FI915210A (fi) 1992-05-07
FI915210A0 (fi) 1991-11-05
IE913862A1 (en) 1992-05-22
EP0484870A3 (en) 1992-09-02
EP0484870A2 (en) 1992-05-13
EP0742015A1 (en) 1996-11-13
CA2055062A1 (en) 1992-05-07
AU649275B2 (en) 1994-05-19
AU8687991A (en) 1993-04-01
ZA918738B (en) 1992-07-29
JPH04264089A (ja) 1992-09-18

Similar Documents

Publication Publication Date Title
NO914521L (no) Laser
DE69116716D1 (de) Ringlaser
ES2019565A4 (es) Procedimiento y dispositivo para peletizar
MX9101956A (es) Prodrogas para beta-lactamasa y usos de los mismos
LV10086A (lv) CIV - inhibejosi benzolacetamida atvasinajumi
DK0469887T3 (da) Acetamidderivater
MX9100415A (es) Piridinas substituidas y procedimiento para su obtencion
MX9100845A (es) Nuevas tienodiazepinas y procedimiento para su preparacion
DE69118563D1 (de) Laservorrichtung
MX9100811A (es) Indolonaftiridinas y procedimiento para su preparacion
MX9101794A (es) Compuestos de trifendioxazina y procedimiento para su preparacion
MX9100779A (es) Compuestos azabiciclicos y procedimiento para su preparacion
MX9101592A (es) Tieno 3,2-b piran-5,7-dionas substituidas y procedimiento para su obtencion
BR7002425U (pt) Regua para normografar
MX9200120A (es) Compuestos de bipiridilo y procedimiento para su preparacion
ES297087Y (es) Aparato para estereotaxia
BR7001213U (pt) Conjunto para colorir
BR9004936A (pt) Misturas inciadoras isentas de chumbo e bario para espoletas
PT8180T (pt) Sifao para lava-loicas
BR7000049U (pt) Cone para seguranca
BR6800532U (pt) Trailler para shows e comicios
BR7100296U (pt) Absorvente para ostoma
PT8655T (pt) Suporte para engraxar sapatos
BR6901086U (pt) Conjunto para turbinamento
BR6900559U (pt) Conjunto para fazer picoles